En forskningsundersøgelse, der sammenligner, hvor godt forskellige doser af medicinen NN0519-0130 sænker blodsukkeret hos mennesker med type 2-diabetes
Undersøgelse af sikkerheden og effektiviteten af en gang om ugen NNC0519-0130 hos deltagere med type 2-diabetes - en dosisbestemmelsesundersøgelse
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Campbelltown, New South Wales, Australien, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australien, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australien, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australien, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australien, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australien, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australien, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australien, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australien, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australien, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australien, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australien, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australien, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australien, 6160
- Fremantle Hospital
-
-
-
-
-
Québec, Canada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Canada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Canada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Canada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Canada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Canada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Canada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Canada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Canada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Canada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Canada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Canada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
California
-
Chula Vista, California, Forenede Stater, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Forenede Stater, 93720
- Valley Research
-
Inglewood, California, Forenede Stater, 90301
- 310 Clinical Research
-
La Mesa, California, Forenede Stater, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Forenede Stater, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Forenede Stater, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Forenede Stater, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Forenede Stater, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Forenede Stater, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Forenede Stater, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Forenede Stater, 91602
- Med Partners, Inc.
-
Torrance, California, Forenede Stater, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Forenede Stater, 92780
- University Clin Investigators
-
Walnut Creek, California, Forenede Stater, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Forenede Stater, 33756
- Innovative Research of W FL
-
Miami, Florida, Forenede Stater, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Forenede Stater, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Forenede Stater, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Forenede Stater, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Forenede Stater, 20745
- MD Medical Research
-
Rockville, Maryland, Forenede Stater, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Forenede Stater, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Forenede Stater, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Forenede Stater, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Forenede Stater, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Forenede Stater, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Forenede Stater, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Forenede Stater, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Forenede Stater, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Forenede Stater, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Forenede Stater, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Forenede Stater, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Forenede Stater, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Forenede Stater, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Forenede Stater, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Forenede Stater, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Forenede Stater, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Forenede Stater, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Forenede Stater, 75230
- Zenos Clinical research
-
Forney, Texas, Forenede Stater, 75126
- Care United Research, LLC
-
Houston, Texas, Forenede Stater, 77004
- Endocrine Associates Houston
-
Houston, Texas, Forenede Stater, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Forenede Stater, 75039
- Tekton Research
-
Lewisville, Texas, Forenede Stater, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Forenede Stater, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Forenede Stater, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Forenede Stater, 23606
- TPMG Clinical Research
-
-
-
-
-
Bengaluru, Indien, 560054
- MS Ramaiah
-
New Delhi, Indien, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Indien, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Indien, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Indien, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Indien, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Indien, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japan, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
Free State
-
Bloemfontein, Free State, Sydafrika, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Sydafrika, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Sydafrika, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Sydafrika, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Sydafrika, 4170
- Dr T Padayachee
-
-
-
-
-
Seoul, Sydkorea, 05505
- Asan Medical Center
-
Seoul, Sydkorea, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Sydkorea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Sydkorea, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Sydkorea, 13620
- Seoul National University Bundang Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentel: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentel: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentel: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentel: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Aktiv komparator: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Tidsramme: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Tidsramme: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Tidsramme: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NN9541-4945
- U1111-1291-9196 (Anden identifikator: World Health Organization (WHO))
- jRCT2031230704 (Registry Identifier: JRCT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .